

# Alessandra Vergori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/930299/publications.pdf>

Version: 2024-02-01

55  
papers

1,128  
citations

516561

16  
h-index

434063

31  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2302  
citing authors

#	ARTICLE	IF	CITATIONS
1	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	1.1	137
2	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 286.e7-286.e13.	2.8	104
3	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020, 82, 38-47.	1.0	88
4	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	1.8	87
5	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. <i>Clinical Infectious Diseases</i> , 2022, 75, e552-e563.	2.9	79
6	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	1.2	46
7	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021, 82, 58-66.	1.7	44
8	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	1.0	39
9	COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1796-1804.	2.5	38
10	Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. <i>Annals of Medicine</i> , 2021, 53, 295-301.	1.5	33
11	Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 515-519.	1.1	26
12	Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. <i>BMC Infectious Diseases</i> , 2017, 17, 182.	1.3	25
13	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	2.3	24
14	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	1.3	21
15	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, 639970.	1.2	20
16	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7942.	1.8	20
17	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	1.0	19
18	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. <i>BMC Infectious Diseases</i> , 2018, 18, 25.	1.3	18
20	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	0.8	18
21	Hepatic Kaposi's sarcoma in a patient affected by AIDS: Correlation between histology and imaging. <i>Journal of Ultrasound</i> , 2012, 15, 215-219.	0.7	16
22	Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature. <i>IDCases</i> , 2015, 2, 109-115.	0.4	16
23	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-2014. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	1.3	15
24	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	1.3	14
25	Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1277-1285.	1.3	14
26	Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. <i>PLoS ONE</i> , 2017, 12, e0187095.	1.1	14
27	Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. <i>HIV Medicine</i> , 2018, 19, 578-584.	1.0	13
28	HIV MDR is still a relevant issue despite its dramatic drop over the years. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1301-1310.	1.3	13
29	Management of Spontaneous Bleeding in COVID-19 Inpatients: Is Embolization Always Needed?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4119.	1.0	13
30	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	1.6	11
31	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018, 21, e25083.	1.2	10
32	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	1.3	8
33	Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH. <i>Journal of Clinical Medicine</i> , 2022, 11, 1546.	1.0	8
34	Listeria meningoenzephalitis and anti-GQ1b antibody syndrome. <i>Infection</i> , 2016, 44, 543-546.	2.3	6
35	Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. <i>Infection</i> , 2019, 47, 929-935.	2.3	6
36	Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , 2021, 22, 519-525.	1.0	6

#	ARTICLE	IF	CITATIONS
37	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. <i>Frontiers in Pharmacology</i> , 2021, 12, 621676.	1.6	6
38	High Levels of TRIM5 $\alpha$ Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. <i>Cells</i> , 2021, 10, 1207.	1.8	6
39	SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. <i>International Journal of Infectious Diseases</i> , 2020, 101, 38-41.	1.5	4
40	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The STORE Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 290-294.	0.9	3
41	Human immunodeficiency virus (HIV) and coronavirus disease 2019; impact on vulnerable populations and harnessing lessons learnt from HIV programmes. <i>New Microbes and New Infections</i> , 2021, 41, 100857.	0.8	3
42	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. <i>Viruses</i> , 2022, 14, 970.	1.5	3
43	Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	1.6	2
44	Persistent gamma delta T cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy-induced cure. <i>Journal of Viral Hepatitis</i> , 2020, 27, 754-756.	1.0	2
45	Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. <i>Scientific Reports</i> , 2021, 11, 11334.	1.6	2
46	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 75-87.	0.4	2
47	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.1	2
48	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. <i>Nutrients</i> , 2021, 13, 3571.	1.7	2
49	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa566.	0.4	2
50	Lower proportion of sustained virologic response and higher residual HCV viremia at the end of direct-acting antivirals treatment in HIV/HCV co-infected as compared with HCV mono-infected patients: meaning and correlates. <i>Journal of Hepatology</i> , 2017, 66, S510.	1.8	1
51	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load $\geq 50$ copies/mL: does estimated glomerular filtration rate matter?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106154.	1.1	1
52	Prevalence and clinical outcome of hepatitis Delta infection in patients with HIV/HBV coinfection. <i>Journal of Hepatology</i> , 2018, 68, S493.	1.8	0
53	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	1.3	0
54	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 135-142.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. <i>Infezioni in Medicina</i> , 2020, 28, 576-586.	0.7	0